MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 225 filers reported holding MYRIAD GENETICS INC in Q3 2017. The put-call ratio across all filers is 1.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $5,000 | 0.0% | 200 | +25.0% | 0.00% | -33.3% |
| Q3 2019 | $5,000 | +25.0% | 160 | 0.0% | 0.00% | +50.0% |
| Q2 2019 | $4,000 | -20.0% | 160 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $5,000 | 0.0% | 160 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $5,000 | -44.4% | 160 | -20.0% | 0.00% | -40.0% |
| Q3 2018 | $9,000 | +28.6% | 200 | 0.0% | 0.01% | +25.0% |
| Q2 2018 | $7,000 | +16.7% | 200 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $6,000 | -14.3% | 200 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $7,000 | -99.9% | 200 | -33.3% | 0.00% | -42.9% |
| Q3 2017 | $10,854,000 | +40.0% | 300 | 0.0% | 0.01% | +40.0% |
| Q2 2017 | $7,752,000 | +39.7% | 300 | 0.0% | 0.01% | +25.0% |
| Q1 2017 | $5,550,000 | +110900.0% | 300 | 0.0% | 0.00% | +33.3% |
| Q4 2016 | $5,000 | -50.0% | 300 | 0.0% | 0.00% | -57.1% |
| Q2 2016 | $10,000 | +100.0% | 300 | +114.3% | 0.01% | +133.3% |
| Q1 2016 | $5,000 | – | 140 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,750,000 | $75,900,000 | 2.61% |
| PFM Health Sciences, LP | 2,025,681 | $55,909,000 | 1.90% |
| Tieton Capital Management, LLC | 118,456 | $3,269,000 | 1.83% |
| Altium Capital Management LP | 190,000 | $5,244,000 | 1.45% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,846,490 | $50,963,000 | 1.03% |
| EARNEST PARTNERS LLC | 6,316,365 | $174,332,000 | 1.01% |
| Glenview Capital Management | 1,679,747 | $46,361,000 | 0.99% |
| Zebra Capital Management LLC | 14,209 | $392,000 | 0.63% |
| AIMZ Investment Advisors, LLC | 44,185 | $1,220,000 | 0.48% |
| Phocas Financial Corp. | 132,101 | $3,646,000 | 0.46% |